ArticleBMC health services research2014
Quality use of medicines within universal health coverage: challenges and opportunities.
Article in BMC health services research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Quality of medicines for life-threatening pregnancy complications in low- and middle-income countries: A systematic review.PloS one · 2020Pooled it
- A Review of Realizing the Universal Health Coverage (UHC) Goals by 2030: Part 1- Status quo, Requirements, and Challenges.Journal of medical systems · 2015Pooled it
- Inequality in benefit distribution of reducing the outpatient cost-sharing: evidence from the outpatient pooling scheme in China.Frontiers in public health · 2024Article
- The effect of prescription patterns on the performance of the pharmacy department of a Regional Referral Hospital, Uganda.Journal of pharmaceutical policy and practice · 2024Article
- National pharmacy associations in the commonwealth: current scenario and future needs to maximise effective contributions of the pharmacy profession towards universal health coverage.Journal of pharmaceutical policy and practice · 2021Article
- Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia.BMJ global health · 2021Article
- Cost containment by peer prior authorization program for second line treatment in patients with retinal disease.Israel journal of health policy research · 2021Article
- Evaluation of Rational Use of Medicine Using WHO/INRUD Core Drug Use Indicators at Teda and Azezo Health Centers, Gondar Town, Northwest Ethiopia.Integrated pharmacy research & practice · 2021Article
- Article
- Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan.International journal for equity in health · 2019Article
- Rationing for medicines by health care providers in Indonesia National Health Insurance System at hospital setting: a qualitative study.Journal of pharmaceutical policy and practice · 2019Article
- Rational prescribing of antibiotics in children under 5 years with upper respiratory tract infections in Kintampo Municipal Hospital in Brong Ahafo Region of Ghana.BMC research notes · 2018Article
- Defining pharmaceutical systems strengthening: concepts to enable measurement.Health policy and planning · 2017Review
- Essential medicines for universal health coverage.Lancet (London, England) · 2017Review
- Individual capacity-building approaches in a global pharmaceutical systems strengthening program: a selected review.Journal of pharmaceutical policy and practice · 2017Article
- Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform.Bulletin of the World Health Organization · 2015Article
- Medicines and universal health coverage: challenges and opportunities.Journal of pharmaceutical policy and practice · 2015Article
- Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand.Journal of pharmaceutical policy and practice · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedicines are a major driver of quality, safety, equity, and cost of care in low and middle-income country health systems. Universal health coverage implementers must explicitly address appropriate use of medicines to realize the health benefits of medicines, avoid wasting scarce resources, and sustain the financial viability of universal health coverage schemes. DISCUSSION: Medicines are major contributors to the health and well-being of individuals and populations when used appropriately, and they waste resources and endanger health when used unnecessarily or incorrectly. Stakeholders need to balance inherently competing objectives in the pharmaceutical sector. Emerging and expanding UHC schemes provide potential levers to balance competing system objectives.To use these levers, sustainable universal coverage programs will require a) information systems that can track medicines utilization, expenditures, and quality of medicines use; b) routine monitoring of indicators of medicines availability, access, affordability, and use; c) policies and programs that facilitate appropriate medicines use by prescribers, dispensers, and patients; d) transparency in setting priorities for medicines coverage under resource constraints; and e) a system perspective to engage diverse actors.As they operationalize paths toward universal health coverage and include targeted medicines coverage policies and programs, systems can build on, and innovate, pharmaceutical policy frameworks and management tools from different countries' settings. SUMMARY: Ensuring that medicines which achieve important health outcomes are available, accessible to all, used appropriately, and sustainably affordable is essential for realizing universal health coverage. Stakeholder cooperation and use of information and financing system levers provide opportunities to work toward this goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.